The Manila Times

Men Balance Pro Unveiled: How This Men Balance Pro Supplement Sets New Standard in Men’s Hormonal Balance & Daily Wellness Support

Men Balance Pro is a men’s wellness formula designed for hormonal balance, prostate comfort, and daily vitality. Discover its ...
The Manila Times

Garaherb Unveiled: How This Garaherb Male Supplement Sets New Standards in Men’s Health & Daily Wellness Support

Garaherb Unveiled offers a fact-based 2026 overview of the Garaherb male supplement, including ingredients, safety, usage, ...
EurekAlert!

How a common immunosuppressive drug “ATG” injures liver blood vessels

Leveraging human organoid-based mechanistic investigation, researchers reveal how an immunosuppressive drug, antithymocyte ...
Health on MSN

What causes complement 3 glomerulopathy, a rare kidney condition?

Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact cause is unknown.Possible C3G causes include genetic mutations, ...
BioSpace

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Nasdaq

Omeros Wins FDA Approval For YARTEMLEA In Transplant-Associated Thrombotic Microangiopathy

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Morningstar

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...